5114 Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices 

Consumer & Governmental Affairs 

Bureau at (202) 418–0530 (voice), (202) 

418–0432 (TTY). Such requests should 

include a detailed description of the 

accommodation needed. In addition, 

please include a way the FCC can 

contact you if it needs more 

information. Please allow at least five 

days’ advance notice; last-minute 

requests will be accepted, but may be 

impossible to fill. 

Federal Communications Commission. 

Sheryl D. Todd, 

Deputy Secretary. 

[FR Doc. 2015–01811 Filed 1–29–15; 8:45 am] 

BILLING CODE 6712–01–P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Notice: Cancellation of 

Meeting Notice 

January 28, 2015. 

The following Commission meeting 

has been cancelled. No earlier 

announcement of the cancellation was 

possible. 

TIME AND DATE: 2:00 p.m., Thursday, 

January 29, 2015. 

PLACE: The Richard V. Backley Hearing 

Room, Room 511N, 1331 Pennsylvania 

Avenue NW., Washington, DC 20004 

(enter from F Street entrance). 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: It was 

determined by a unanimous vote of the 

Commissioners that the Commission 

consider and act upon the following in 

closed session: Brody Mining, LLC v. 

Secretary of Labor, Docket Nos. WEVA 

2014–82–R, et al. (Issues include 

whether to grant the Secretary of Labor’s 

Emergency Motion for Stay of ALJ’s 

Order Dismissing Pattern-of-Violations 

Notice.) 

Any person attending this meeting 

who requires special accessibility 

features and/or auxiliary aids, such as 

sign language interpreters, must inform 

the Commission in advance of those 

needs. Subject to 29 CFR 2706.150(a)(3) 

and § 2706.160(d). 

CONTACT PERSON FOR MORE INFO: 

Emogene Johnson (202) 434–9935/(202) 

708–9300 for TDD Relay/1–800–877– 

8339 for toll free. 

Sarah L. Stewart, 

Deputy General Counsel. 

[FR Doc. 2015–01921 Filed 1–28–15; 4:15 pm] 

BILLING CODE 6735–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–15–1019] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

The Centers for Disease Control and 

Prevention (CDC), as part of its 

continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies to take this opportunity to 

comment on proposed and/or 

continuing information collections, as 

required by the Paperwork Reduction 

Act of 1995. To request more 

information on the below proposed 

project or to obtain a copy of the 

information collection plan and 

instruments, call 404–639–7570 or send 

comments to Leroy A. Richardson, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an email to omb@cdc.gov. 

Comments submitted in response to 

this notice will be summarized and/or 

included in the request for Office of 

Management and Budget (OMB) 

approval. Comments are invited on: (a) 

Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; (d) ways to 

minimize the burden of the collection of 

information on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology; and (e) estimates of capital 

or start-up costs and costs of operation, 

maintenance, and purchase of services 

to provide information. Burden means 

the total time, effort, or financial 

resources expended by persons to 

generate, maintain, retain, disclose or 

provide information to or for a Federal 

agency. This includes the time needed 

to review instructions; to develop, 

acquire, install and utilize technology 

and systems for the purpose of 

collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information, to search 

data sources, to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Integrating Community Pharmacists 

and Clinical Sites for Patient-Centered 

HIV Care (OMB No. 0920–1019, expires 

05/31/2017)—Revision—National 

Center for HIV/AIDS, Viral Hepatitis, 

STD, and TB Prevention, Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Medication Therapy Management 

(MTM) is a group of pharmacist 

provided services that is independent 

of, but can occur in conjunction with, 

provision of medication. MTM 

encompasses a broad range of 

professional activities and cognitive 

services within the licensed 

pharmacists’ scope of practice and can 

include monitoring prescription filling 

patterns and timing of refills, checking 

for medication interactions, patient 

education, and monitoring of patient 

response to drug therapy. 

HIV specific MTM programs have 

demonstrated success in improving HIV 

medication therapy adherence and 

persistence. While MTM programs have 

been shown to be effective in increasing 

medication adherence for HIV-infected 

persons, no MTM programs have been 

expanded to incorporate primary 

medical providers in an effort to 

establish patient-centered HIV care. To 

address this problem CDC has entered 

into a public-private partnership with 

Walgreen Company (a.k.a Walgreens 

pharmacies, a national retail pharmacy 

chain) to develop and implement a 

model of HIV care that integrates 

community pharmacists with primary 

medical providers for patient-centered 

HIV care. The model program will be 

implemented in ten sites and will 

provide patient-centered HIV care for 

approximately 1,000 persons. 

The patient-centered HIV care model 

will include the core elements of MTM 

as well as additional services such as 

individualized medication adherence 

counseling, active monitoring of 

prescription refills and active 

collaboration between pharmacists and 

medical clinic providers to identify and 

resolve medication related treatment 

problems such as treatment 

effectiveness, adverse events and poor 

adherence. The expected outcomes of 

the model program are increased 

retention in HIV care, adherence to HIV 

medication therapy and viral load 

suppression. 

On 16 May 2014, OMB approved the 

collection of standardized information 

from ten project sites over the three-year 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices 5115 

project period and one retrospective 

data collection during the first year of 

the three-year project period. The 

retrospective data collection will 

provide information about clients’ 

baseline characteristics prior to 

participation in the model program 

which is needed to compare outcomes 

before and after program 

implementation. Minor formatting 

revisions are requested to the previously 

approved data collection forms. Lastly, 

CDC newly requests approval to 

conduct key informant interviews with 

program clinic and pharmacy staff in 

order to evaluate the program processes 

and to collect time and cost data which 

will be used to estimate the cost of the 

model program. The key informant 

interviews and time and cost data are 

additional data collections from the 

original OMB approval. 

Pharmacy, laboratory and medical 

data will be collected through 

abstraction of all participant clients’ 

pharmacy and medical records. 

Pharmacy, laboratory and medical data 

are needed to monitor retention in care, 

adherence to therapy, viral load 

suppression and other health outcomes. 

Program specific data, such as the 

number of MTM elements completed 

per project site and time spent on 

program activities, will be collected by 

program. Qualitative data will be 

gathered from program staff through inperson or telephone interviews. 

The data collection will allow CDC to 

conduct continuous program 

performance monitoring which includes 

identification of barriers to program 

implementation, solutions to those 

barriers, and documentation of client 

health outcomes. Performance 

monitoring will allow the model 

program to be adjusted, as needed, in 

order to develop a final implementation 

model that is self-sustaining and which 

can be used to establish similar 

collaborations in a variety of clinical 

settings. Collection of cost data will 

allow for the cost of the program to be 

estimated. 

There is no cost to participants other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Clinic Data Manager ...... Project clinic characteristics form ........................ 10 3 30/60 15 

Pharmacist ..................... Project pharmacy characteristics form ................ 10 3 30/60 15 

Clinic Data Manager ...... Patient Demographic Information form ............... 10 100 5/60 83 

Clinic Data Manager ...... Initial patient information form ............................. 10 100 1 1,000 

Clinic Data Manager ...... Quarterly patient information form ....................... 10 400 30/60 2,000 

Pharmacist ..................... Pharmacy record abstraction form ...................... 10 400 30/60 2,000 

Key informants ............... Interviewer data collection worksheet ................. 60 2 30/60 60 

Clinic staff ...................... Clinic cost form .................................................... 20 2 10 400 

Pharmacy staff ............... Pharmacy cost form ............................................ 20 2 10 400 

Total ........................ .............................................................................. ........................ ........................ ........................ 5,973 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01698 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices: Notice of Charter 

Amendment 

This gives notice under the Federal 

Advisory Committee Act (Pub. L. 92– 

463) of October 6, 1972, that the 

Advisory Committee on Immunization 

Practices, Centers for Disease Control 

and Prevention (CDC), Department of 

Health and Human Services (HHS), has 

amended their charter to reflect the 

change in the filing date. The amended 

filing date is January 13, 2015. 

For information, contact Dr. Larry 

Pickering, Designated Federal Officer, 

Advisory Committee on Immunization 

Practices, HHS, CDC, 1600 Clifton Road 

NE., Mailstop E05, Atlanta, Georgia 

30333, telephone (404) 639–8562 or fax 

(404) 639–8626. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01767 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee to the Director 

(ACD), Centers for Disease Control and 

Prevention—Health Disparities 

Subcommittee (HDS) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned subcommittee: 

Time and Date: 11:00 a.m.–12:30 p.m. EST, 

February 26, 2015. 

Place: This meeting will be held by 

teleconference. 

Status: This meeting is open to the public, 

limited only by the availability of telephone 

ports. The public is welcome to participate 

during the public comment, which is 

tentatively scheduled from 12:15 to 12:30 

p.m. To participate in the teleconference, 

please dial (866) 763–0273 Passcode: 

6158968. 

Purpose: The Subcommittee will provide 

advice to the CDC Director through the ACD 

on strategic and other health disparities and 


asabaliauskas on DSK5VPTVN1PROD with NOTICES